Biocomposites’ Stimulan (Image courtesy of Biocomposites)
Biocomposites, which manufactures infection-control products for bone and soft tissue, has announced that it plans to make a significant investment in its U.S. sales force in 2021.
From May through November 2020, the company inked distribution deals in Saudi Arabia, the United Arab Emirates, Australia, Norway, Hungary, the Baltic region, Netherlands, Belgium, Luxembourg and Denmark.
In April 2020, the company’s lead orthopaedic product, Stimulan, became the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue. Stimulan is formulated to lower rates of reinfection and can be placed directly into infected and non-infected sites, according to the UK-based company.
Biocomposites also plans to seek regulatory approval for Stimulan in other countries and to launch its Stimulan Rapid Cure 3cc product in multiple countries in 2021. Stimulan Rapid Cure 3cc was designed specifically for smaller voids in the foot and ankle and for orthopaedic reconstruction and trauma procedures. Biocomposites launched it in the U.S. in March 2020 and the following month, named a new president, Will Connelly, to focus on the Americas.
